Group 1: Fudan Zhangjiang - Fudan Zhangjiang is advancing its DC platform and photodynamic technology platform, with multiple antibody-drug conjugates in various clinical stages for treating cancers such as triple-negative breast cancer, bladder cancer, and gastric cancer [1] - The company is conducting Phase III clinical studies for anti-Trop2 antibody-drug conjugates and has completed the first subject enrollment for a clinical trial involving aminolevulinic acid granules for non-muscle invasive bladder cancer [1] - Fudan Zhangjiang plans to increase R&D investment to further promote the progress of its research projects [1] Group 2: Xiangyu Medical - Xiangyu Medical's research indicates a clear and significant demand for non-invasive brain-machine interfaces in rehabilitation, sleep monitoring, and attention enhancement [2] - The company has developed two EEG collection devices that have received Class II medical device registration and expects to obtain multiple registrations for brain-machine interface products in the second half of the year [2] - Xiangyu Medical's sales strategy involves starting with top-tier hospitals and gradually expanding to lower-tier hospitals and community health centers, with plans to enter the home market [2]

根据市场公开信息及7月15日披露的机构调研信息，知名私募誉辉资本近期对1家上市公司进行了调研， 相关名单如下： 誉辉资本管理（北京）有限责任公司成立于2015年10月22日，注册资本1000万元人民币，为私募证券投 资基金管理人。 1）翔宇医疗 （誉辉资本参与公司现场参观&线上交流） 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 调研纪要：翔宇医疗机构调研显示，脑机接口在康复领域应用前景明确且需求巨大。非侵入式脑机接口 应用广泛，包括康复、睡眠监测、脑放松、注意力提升等。公司已有两款脑电采集装置获二类医疗器械 注册证，预计下半年会获得多款以"脑机接口"命名的二类医疗器械注册证。公司在非侵入式脑电采集方 面研发了专项技术，解决了电极与头皮之间的接触不良问题，提高了连接的稳定性和用户体验。现阶段 脑电采集装置主要是自研自用，未来可能会向第三方开放销售。公司将现有的康复设备升级为脑机接口 产品具备显著的成本竞争力，市场定价会考虑医院支付能力和医保支付标准。国家医保局对脑机接口康 复收费持积极态度，部分省市已出台收费指导目录。销售策略是从顶 ...

Policy Developments - The National Medical Products Administration (NMPA) released the "Quality Management Specifications for Online Sales of Medical Devices," effective from October 1, 2025, which emphasizes qualification review, information transparency, and risk prevention for online medical device sales [1] Drug and Device Approvals - Insilico Medicine's INS018_055 tablet is expected to receive breakthrough therapy designation for treating idiopathic pulmonary fibrosis [2] - Yuyuan Pharmaceutical's injectable Ganciclovir has passed the consistency evaluation for generic drugs, which will enhance the company's market share and competitiveness [3] - Warner Pharmaceuticals' Bismuth Potassium Citrate Granules have also passed the consistency evaluation for generic drugs, benefiting future market sales [4] - Changchun High-tech's subsidiary, Jinsai Pharmaceutical, received approval for clinical trials of Fuxin Qibai monoclonal antibody injection, aimed at treating endometriosis [5] Financial Reports - Yunnan Baiyao reported a Q1 2025 net profit of 1.935 billion yuan, a 13.67% increase year-on-year, with total revenue of 10.841 billion yuan, up 0.62% [6] - WuXi AppTec's Q1 2025 net profit surged by 89.06% to 3.672 billion yuan, driven by revenue growth and operational efficiency improvements [7][8] - Kefu Medical's 2024 annual report showed a net profit increase of 22.6% to 312 million yuan, with revenue of 2.983 billion yuan, up 4.53% [9] - Hongbo Pharmaceutical's Q1 2025 net profit increased by 226.47% to 11.974 million yuan, with revenue of 16.9 million yuan, up 29.61% [10] Capital Market Activities - Jiangsu Hengrui Medicine has received approval from the China Securities Regulatory Commission for its Hong Kong IPO, planning to issue up to 815.1 million shares [11] - Merck announced its acquisition of SpringWorks for approximately $3.9 billion in equity value [12] - China Merchants Bio intends to increase its stake in Renfu Pharmaceutical by 0.5%-1% within six months, reflecting confidence in the company's future [13] Industry Developments - Xiangyu Medical expects to obtain registration certificates for seven robotic products by 2025, focusing on rehabilitation and other medical applications [14] - Soundon Medical has formed a strategic partnership with MED-EL's BHM to advance global bone conduction hearing solutions [16] - Hanyu Pharmaceutical signed a comprehensive cooperation agreement with Huawei Cloud to focus on "AI Smart Drugs" in drug development [17] Public Sentiment Alerts - Innovative Medical announced that shareholder Shanghai Guanghuan Technology reduced its stake by 3.41 million shares, representing 0.8191% of the total circulating shares [18]